Review · PMID 41241376
Host Defense Peptides with Immunoregulatory Mechanisms in IBD — VialBase Research
KPV grouped with host defense peptides (HDPs) for IBD treatment
Last updated · 2025 · Various · Various
Key findings
- KPV grouped with host defense peptides (HDPs) for IBD treatment
- Immunoregulatory mechanism: NF-kB pathway downregulation
- Modulates cytokine release and restores homeostasis
- HDPs offer reduced side effects compared to conventional IBD therapy
- KPV classified as alpha-MSH derivative among antimicrobial peptide families
KPV Among Host Defense Peptides for IBD (PMID: 41241376)
Review Scope
- Comprehensive review of host defense peptides (HDPs) for inflammatory bowel disease
- Covers defensins, cecropins, microcins, brevinins, PrAMPs, and alpha-MSH derivatives
- KPV classified as alpha-MSH-derived HDP
KPV Mechanism in IBD Context
- Downregulates NF-kB pathway (core anti-inflammatory mechanism)
- Modulates cytokine release (TNF-alpha, IL-1beta, IL-6)
- Restores intestinal homeostasis
- Reduces side effects compared to conventional immunosuppressants
Relevance
Validates KPV within the broader host defense peptide therapeutic landscape for IBD. Positions it alongside naturally occurring antimicrobial and immunoregulatory peptides, supporting its therapeutic rationale for gut inflammatory conditions.